Fitzgerald Thomas A received an award of 185,000 derivative securities in Transcode Therapeutics, Inc. on 2026-09-09. The award accounts for about 100.0% of his resulting derivative securities position, meaning the entire reported holding consisted of securities from this transaction.

Key Highlights

  • The filing reports an award of 185,000 derivative securities to Fitzgerald Thomas A.
  • Fitzgerald Thomas A serves as chief financial officer of Transcode Therapeutics, Inc.
  • Following the transaction on 9 September 2026, his reported derivative securities position was 185,000.

Fitzgerald Thomas A received 185,000 derivative securities in Transcode Therapeutics, Inc (NASDAQ: RNAZ). on 9 September 2026. The award left his resulting derivative securities position at 185,000, with the transaction representing about 100.0% of that holding.

185,000 Derivative Securities Awarded

Fitzgerald Thomas A is the chief financial officer of Transcode Therapeutics, Inc. The filing reports transaction code A. His post-transaction position stood at 185,000 derivative securities. The transaction represents about 100.0% of the resulting derivative securities position reported for Fitzgerald Thomas A.

Award Represents About 100.0% of Resulting Holding

The filing states that the transaction represents about 100.0% of the 185,000 derivative securities held after the transaction. Transaction code A denotes an award, grant, or other Acquisition from the company.